Matt Hancock

Coronavirus vaccine developer AstraZeneca plc (NYSE: AZN) said Tuesday that a Phase 3 trial being conducted with Oxford University has been put on hold for a safety review. Several experts said they're not overly concerned the development will derail the likelihood of a COVID-19...